Who is responsible for what?
- PMID: 2093630
- DOI: 10.1111/j.1472-8206.1990.tb00077.x
Who is responsible for what?
Abstract
During the phase I trials, from the juridical point of view, the responsibilities are shared between the pharmaceutical company and the physician who manages the trial. The pharmaceutical company is responsible for the product, the choice of methodology and respect for the regulations. On the financial side, the company is liable for paying any damages. While the trial is being conducted, the physician is responsible both for the choice of the healthy volunteers and for their care.
Similar articles
-
With whom does the French drug industry want to work for phase I?Fundam Clin Pharmacol. 1990;4 Suppl 2:207s-211s. doi: 10.1111/j.1472-8206.1990.tb00081.x. Fundam Clin Pharmacol. 1990. PMID: 2093633
-
Post-marketing surveillance in the UK (1984).Br J Clin Pharmacol. 1986;22 Suppl 1(Suppl 1):71S-75S. doi: 10.1111/j.1365-2125.1986.tb02986.x. Br J Clin Pharmacol. 1986. PMID: 3567035 Free PMC article. No abstract available.
-
Addressing Pharmaceutical Injuries: The US Landscape.Clin Pharmacol Ther. 2018 Mar;103(3):384-385. doi: 10.1002/cpt.774. Epub 2017 Aug 29. Clin Pharmacol Ther. 2018. PMID: 28850676
-
[The safety and registration of pharmaceuticals from the point of view of the medical practitioner].Anaesthesist. 2002 Dec;51(12):1029-37; quiz 1037-8. doi: 10.1007/s00101-002-0438-y. Anaesthesist. 2002. PMID: 12583351 Review. German. No abstract available.
-
Good clinical practices in phase I studies.Fundam Clin Pharmacol. 1990;4 Suppl 2:163s-165s. doi: 10.1111/j.1472-8206.1990.tb00074.x. Fundam Clin Pharmacol. 1990. PMID: 2093627 Review.
Cited by
-
Influence of the Purkinje-muscle junction on transmural repolarization heterogeneity.Cardiovasc Res. 2014 Sep 1;103(4):629-40. doi: 10.1093/cvr/cvu165. Epub 2014 Jul 3. Cardiovasc Res. 2014. PMID: 24997066 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources